Bryan Spiegelberg

Bryan Spiegelberg

As a Ph.D. candidate, Bryan participated in the studies related to pharmacologic targets of lithium, characterizing the bishosphate nucleotidase (BPNT1) he cloned to understand its role as a toxic target of lithium in the kidney and gut epithelium. He also studied the role of its substrates and /or products in relation to lithium induced nephrogenic diabetes insipidus. He defended his thesis, Bisphosphate 3'-Nucleotidase: A Novel Target of Lithium Therapy, in August 2002.

Bryan is currently a post-doc in Dr. Heidi Hamm's Pharmacology Lab at Vanderbilt University. He is working on molecular interactions of G proteins with receptors and effectors.


Return to the York Lab Home Page